Test Directory

BCR::ABL1 t(9;22)(q34;q11) Diagnostic (for suspected CML)

Containers - Adult

RedCapTubeEDTAKE9ml.jpg
Red Cap Tube EDTA KE 9ml
Volume Range

10-15ml Peripheral blood or bone marrow specimen

Additive per Container

EDTA

Laboratory Site

WGH
Crewe Road South
Edinburgh
EH4 2XU
Telephone: 0131 537 1000

Transport arrangements

Blood and bone marrow specimens should ideally arrive within 24 hours of collection (maximum of 48 hours).  Specimens should arrive no later than 3.30pm on Friday.  Samples should be sent to the following address:

Western General Hospital

Haematology/Biochemistry Combined Reception

Immunophenotyping Laboratory

Crewe Road

Edinburgh

EH4 2XU​

 

See also "Specimen transportation".

Sample storage arrangements

Samples should be stored at room temperature. See specimen requirements.​

How to request

Requests may be made using our request form or via TRAK.  Please refer to our detailed requesting instructions.  The HMDS request form can be located here.​

HMDS request form PDF_v5.pdf

Availability

Monday-Friday 9am-5pm

Anticipated turnaround

Results for suspected Chronic Myeloid Leukaemia (CML) should be expected within 3 working days.  See results.

What happens if the result is positive or abnormal

The requesting clinician will be contacted where results are clinically significant. Please ensure details are included on request form.

Static information/disclaimer


This test is not accredited to ISO 15189:2012

General additional information

This is a diagnostic test for suspected CML cases. For follow up MRD monitoring samples, please refer to the BCR::ABL1/ABL1 MRD monitoring.

The BCR::ABL1 fusion oncogene is the hallmark of CML. In the majority of cases, this arises as a result of a translocation between chromosome 9 and 22 (Philadelphia Chromosome). Based on the specific breakpoints of the rearrangement, several different BCR::ABL1 fusion transcripts can be expressed.

This test screens for the most frequent BCR::ABL1 fusion transcripts (E1A2, E13A2 and E14A2) associated with Chronic Myeloid Leukaemia. It will not detect rare BCR-ABL1 fusion transcripts such as E19A2. See testing for additional information

For clinical advice on appropriate investigations and advice for the interpretation of test results, please see contact us​.